{"commentary":{"count":175,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":97,"youtube":42,"podcast":36},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04338269\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"CONTACT-03","nct_id":"NCT04338269","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=contact-03-nct04338269. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"CONTACT-03","arms":[{"description":"Participants will receive atezolizumab every 3 weeks on Day 1 of each 21-day cycle (1 cycle=21 days) plus oral tablets of cabozantinib every day.","label":"Atezo+Cabo","type":"EXPERIMENTAL"},{"description":"Participants will receive cabozantinib every day.","label":"Cabozantinib","type":"ACTIVE_COMPARATOR"}],"collaborators":["Exelixis","Chugai Pharmaceutical"],"completion_date":{"date":"2025-03-24","type":"ACTUAL"},"conditions":["Carcinoma, Renal Cell"],"enrollment":{"count":522,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Atezolizumab","type":"DRUG"},{"name":"Cabozantinib","type":"DRUG"}],"last_update":"2026-03-19","lead_sponsor":"Hoffmann-La Roche","official_title":"A Phase III, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination With Cabozantinib Versus Cabozantinib Alone in Patients With Inoperable, Locally Advanced, or Metastatic Renal Cell Carcinoma Who Experienced Radiographic Tumor Progression During or After Immune Checkpoint Inhibitor Treatment","overall_status":"TERMINATED","phases":["PHASE3"],"primary_completion_date":{"date":"2023-01-03","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS) as Assessed by an Independent Review Facility (IRF) (IRF-PFS) According to RECIST v1.1","timeFrame":"From randomization to the first occurrence of PD according to RECIST v1.1, or death from any cause, whichever occurred first (up to 2 years 5 months)"},{"measure":"Overall Survival (OS)","timeFrame":"From randomization to death due to any cause (up to 2 years 5 months)."}],"references":[{"citation":"Pal SK, Albiges L, Tomczak P, Suarez C, Voss MH, de Velasco G, Chahoud J, Mochalova A, Procopio G, Mahammedi H, Zengerling F, Kim C, Osawa T, Angel M, Gupta S, Khan O, Bergthold G, Liu B, Kalaitzidou M, Huseni M, Scheffold C, Powles T, Choueiri TK. Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2023 Jul 15;402(10397):185-195. doi: 10.1016/S0140-6736(23)00922-4. Epub 2023 Jun 5.","pmid":"37290461","type":"DERIVED"},{"citation":"Yang Y, Psutka SP, Parikh AB, Li M, Collier K, Miah A, Mori SV, Hinkley M, Tykodi SS, Hall E, Thompson JA, Yin M. Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma. Cancer Med. 2022 Aug;11(16):3106-3114. doi: 10.1002/cam4.4679. Epub 2022 Mar 18.","pmid":"35304832","type":"DERIVED"}],"start_date":{"date":"2020-07-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment","url":"https://clinicaltrials.gov/study/NCT04338269"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/contact-03-nct04338269"}